Oral Session 3-8D Indolent lymphoma: Clinical studies

[OS3-8D-4] Retrospective analysis of R-Benda as first-line treatment for indolent B cell lymphoma

Kayo Harada-Shirado¹, Masahiko Fukatsu¹, Takahiro Sano^1,3, Satoshi Kimura¹, Hiroshi Takahashi¹, Akiko Shichishima-Nakamura¹, Hiroshi Ohkawara¹, Kazuei Ogawa^1,2, Hiroyuki Kanbayashi³, Yurie Saitou³, Satoru Kimura³, Masumi Sukegawa⁷, Kazuko Akutsu⁵, Youichi Hamazaki⁵, Tatsuyuki Kai⁴, Masayuki Mita⁶, Masatsugu Ohta⁷, Takayuki Ikezoe¹ (1.Department of Hematology, Fukushima Medical University, Fukushima, Japan, 2.Preparing section for new faculty of medical science, FMU, 3.Department of Hematology, Ohta Nishinouchi Hospital, Ohta General Hospital Foundation, 4.Department of Hematology, Kita-Fukushima Medical Center, Fukushima, Japan, 5.Iwaki-kyoritsu General Hospital, Iwaki, Japan, 6.Hematology and Oncology Center, Shirakawa Kosei General Hospital, Shirakawa, Japan, 7.Department of Hematology, Fukushima Medical University Aizu Medical Center)